Matches in Nanopublications for { ?s ?p "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 18 of
18
with 100 items per page.
- NP621710.RAkDl0tMBmk7vAFVi9KZrrv0Swy0qMKksTv-H6WlkQTJI130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621710.RAkDl0tMBmk7vAFVi9KZrrv0Swy0qMKksTv-H6WlkQTJI130_provenance.
- NP316547.RAIRbike178KxdEzVX7f4h-wmnOehemqMkTTjGFT6niI4130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP316547.RAIRbike178KxdEzVX7f4h-wmnOehemqMkTTjGFT6niI4130_provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP893449.RAdm-xZofUTzgUGuOQNxRqZkvi2BOkN7CPKTN19zlw7nc130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893449.RAdm-xZofUTzgUGuOQNxRqZkvi2BOkN7CPKTN19zlw7nc130_provenance.
- NP893454.RAmI-WKF_LITzkINfT5XgTu-E1L2P9hyKXIIlx663UXCU130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893454.RAmI-WKF_LITzkINfT5XgTu-E1L2P9hyKXIIlx663UXCU130_provenance.
- NP893456.RAqF-eCSeYmRD9Q0DT1QWSVxQru0wHPr2yMNMQqTRJH78130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893456.RAqF-eCSeYmRD9Q0DT1QWSVxQru0wHPr2yMNMQqTRJH78130_provenance.
- NP893447.RAMojDFXggAts8lQXjAlCQoAc870Aae76dEVmAwBrOkWU130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893447.RAMojDFXggAts8lQXjAlCQoAc870Aae76dEVmAwBrOkWU130_provenance.
- NP893450.RALNg4pbTaBgox9sWgYmIQEi2nmWkMpEwlw_bJK4gSFbw130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893450.RALNg4pbTaBgox9sWgYmIQEi2nmWkMpEwlw_bJK4gSFbw130_provenance.
- NP893452.RAEWl5n2yWUq-56RnDV-piMzftums8Slbt9lcE__I2ick130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893452.RAEWl5n2yWUq-56RnDV-piMzftums8Slbt9lcE__I2ick130_provenance.
- NP893453.RAOPfw0GA92N2VldS6fgotYO_4a4TPGo3EdmJPGMUVnnI130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893453.RAOPfw0GA92N2VldS6fgotYO_4a4TPGo3EdmJPGMUVnnI130_provenance.
- NP893455.RA4cu0dt9G8pn1j_QE9OBSARm4-yT01X-hhmLpixKxTvY130_assertion description "[These results strongly support the utilization of PI3K pathway inhibitors in ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893455.RA4cu0dt9G8pn1j_QE9OBSARm4-yT01X-hhmLpixKxTvY130_provenance.